{
  "questionnaire": {
    "title": "irAKI vs Other AKI Classification Assessment",
    "version": "2.0",
    "timestamp": "Aug 7, 2025",
    "reference": "Sprangers et al. Nature Reviews Nephrology 2022",
    "scale": {
      "type": "9-point Likert",
      "range": "1-9",
      "anchors": {
        "1": "Strongly disagree / Very unlikely",
        "5": "Neutral / Uncertain",
        "9": "Strongly agree / Very likely"
      }
    },
    "questions": [
      {
        "id": "Q1",
        "question": "The temporal relationship between immune checkpoint inhibitor (ICI) exposure and AKI onset strongly supports irAKI diagnosis"
      },
      {
        "id": "Q2",
        "question": "Prerenal causes of AKI have been adequately excluded"
      },
      {
        "id": "Q3",
        "question": "Postrenal/obstructive causes of AKI have been adequately excluded"
      },
      {
        "id": "Q4",
        "question": "Other intrinsic causes of AKI (ATN, contrast nephropathy, other drugs) have been adequately excluded"
      },
      {
        "id": "Q5",
        "question": "Urinalysis findings are consistent with immune-mediated kidney injury"
      },
      {
        "id": "Q6",
        "question": "Laboratory evidence suggests systemic immune activation consistent with irAKI"
      },
      {
        "id": "Q7",
        "question": "Concomitant medications known to cause AKI/ATIN have been adequately assessed and excluded"
      },
      {
        "id": "Q8",
        "question": "The presence of other immune-related adverse events (irAEs) supports the diagnosis of irAKI"
      },
      {
        "id": "Q9",
        "question": "Kidney biopsy is indicated and expected to show findings consistent with immune-mediated injury"
      },
      {
        "id": "Q10",
        "question": "The clinical course and expected response pattern are consistent with irAKI"
      },
      {
        "id": "Q11",
        "question": "Alternative systemic diagnoses for AKI have been systematically excluded"
      },
      {
        "id": "Q12",
        "question": "Overall clinical judgment strongly favors irAKI as the most likely diagnosis"
      },
      {
        "id": "Q13",
        "question": "Infection-related AKI (septic ATN, pyelonephritis, other infectious causes) has been systematically excluded"
      },
      {
        "id": "Q14",
        "question": "Radiologic findings support immune-mediated kidney injury or exclude alternative structural causes"
      },
      {
        "id": "Q15",
        "question": "Baseline renal reserve, age-related changes, and frailty have been appropriately considered in AKI assessment"
      },
      {
        "id": "Q16",
        "question": "The risk-benefit profile supports rechallenge with ICI therapy after AKI recovery"
      }
    ],
    "scoring_guidelines": {
      "interpretation": {
        "1-3": "Evidence strongly against irAKI / Alternative diagnosis likely",
        "4-6": "Uncertain / Requires additional evaluation",
        "7-9": "Evidence strongly supports irAKI / High probability diagnosis"
      },
      "confidence_thresholds": {
        "high_confidence": "≥7 on ≥12 questions with no major contradictions",
        "moderate_confidence": "≥6 on most questions with some uncertainty",
        "low_confidence": "Mixed scores or insufficient evidence"
      },
      "consensus_calculation": {
        "method": "Beta-pooled consensus with confidence adjustment",
        "minimum_agreement": "≥70% of experts within 2 points on final gestalt",
        "debate_threshold": "≥3 point disagreement on any question"
      }
    },
    "clinical_decision_support": {
      "high_probability_iraki": {
        "threshold": "≥7.0 average score",
        "recommendations": [
          "Consider kidney biopsy for confirmation",
          "Initiate corticosteroid therapy",
          "Hold or discontinue ICI therapy",
          "Monitor for other irAEs",
          "Nephrology consultation",
          "Assess rechallenge potential after recovery"
        ]
      },
      "moderate_probability_iraki": {
        "threshold": "5.0-6.9 average score",
        "recommendations": [
          "Kidney biopsy strongly recommended",
          "Exclude alternative causes more thoroughly",
          "Consider empiric steroid trial",
          "Multidisciplinary discussion",
          "Close monitoring with serial assessments",
          "Systematic infection workup in immunocompromised"
        ]
      },
      "low_probability_iraki": {
        "threshold": "<5.0 average score",
        "recommendations": [
          "Focus on alternative AKI causes",
          "Standard AKI management",
          "Continue ICI if oncologically appropriate",
          "Consider irAKI if clinical course changes",
          "Document reasoning for alternative diagnosis",
          "Address baseline CKD and frailty factors"
        ]
      }
    }
  }
}